Highlights

  • 13 Jun 2017
    - Highlights

    EBE Webinar: IP and its crucial role in bringing innovative medicines to patients

    20 June 2017 from 4H30 - 5H30 CET

    Europe has good science and sound Intellectual Property (IP) policies in place. These IP policies and other incentive offered by legislation when medicines are developed play a critical role in companies corporate and product development strategies.
    Read Barbara Freischem's pdf presentation here.
    Coming soon : the full recordng of the webinar.

    Read more |
  • 02 Jun 2017
    - Highlights

    Reinventing the European Advanced Therapies Sector: An Interview with Eduardo Bravo

    In this interview with Eduardo Bravo, CEO of TiGenix and President of the Board of the European Biopharmaceutical Enterprises (EBE), we discuss the increasing challenge for EU biotech companies to commercialise at home, and the accelerating departure of cutting-edge European biotech start-ups through IPOs and, increasingly, mergers and acquisitions.

    Interview by Duane Schulthess/Vitaltransformation.com

    Read more |
  • 30 May 2017
    - Highlights

    Final Call ATMP Survey: Help improve product development and regulation

    Response deadline: 30 June 2017 

    Advanced Therapy Medicinal Products (ATMPs) are medicinal products including gene therapies, somatic cell therapies and tissue engineered products. They are characterised by their innovative character. Despite considerable development activity in this dynamic field, a limited number of ATMPs have received Marketing Authorisation in the European Union. There is a growing urgency to understand which factors are associated with the advancement of ATMPs through the medicines life-cycle.

    Read more |
  • 09 May 2017
    - Highlights

    What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey

    Objective: Biosimilar policies with a focus on uptake have received a lot of attention at national and regional level in the last few years. It is now 10 years since the first biosimilar was approved in the European Union, but do policies in the Member States take the differences between biological medicines and small-molecule generics into account? To map the policy landscape in Europe, European Biopharmaceutical Enterprises (EBE) has conducted a second round of its descriptive survey of pricing and reimbursement policies for off-patent biologicals.
    Read more |
  • 28 Apr 2017
    - Highlights

    Podcast: EBE Plots Path from “Flawed Underfunded Biotech System”

    During DIA’s first DIA BioVenture Day, EBE Executive Director Barbara Freischem delivered a presentation titled Europe’s Flawed and Underfunded Biotech System, which she explores in this exclusive Global Forum podcast.

    Read more |
  • 05 Apr 2017
    - Highlights

    Podcast: How To Support Advanced Therapies and Breakthrough Medicines in Europe

    On the occasion of  the first DIA BioVenture day on 28 March 2017 in Glasgow, Menno Aarnout, Wolfgang Stoiber and EBE's Barbara Freischem discussed options for solutions to support the development and funding of Advanced Therapies and Breakthrough Medicines in Europe.

    Read more |
  • 31 Mar 2017
    - Highlights

    Open Call to all ATMP developers

    Invitation for ATMP-developers to help improve product development and its regulation 

    Advanced Therapy Medicinal Products (ATMPs) are medicinal products including gene therapies, somatic cell therapies and tissue engineered products. They are characterised by their innovative character, frequently addressing disease with high unmet medical need. Despite considerable development activity in this dynamic field, a limited number of ATMPs have received Market Authorisation in the European Union. There is a growing urgency to understand which factors are associated with the advancement of ATMPs through the medicines life-cycle.

    Read more |
  • 15 Mar 2017
    - Highlights

    Biosimilar product labels in Europe: what information should they contain?

    To discuss current labelling of biosimilars in Europe, the European Biopharmaceutical Enterprises (EBE) and the European Association for Bioindustries (EuropaBio) held a multi-stakeholder workshop on the topic of ‘Biosimilar Labelling’, in Brussels, Belgium on 2 February 2016. 

    Read more |
  • 23 Feb 2017
    - Highlights

    New project: success and failure in the development and commercialisation of ATMP products

    With recent developments in innovative technologies, new opportunities arise to address demands of an aging population, as well as for diseases with high unmet medical needs. 

    Read more |
  • 01 Feb 2017
    - Highlights

    Event report from the 5th annual regulatory conference on ATMPs organised by EBE in collaboration with the EMA

    The 5th annual regulatory conference on ATMPs, organised by EBE with the support of the European Medicines Agency (EMA) took place on 16 December 2016, in London, UK. The event saw a packed house - the greatest participation so far.

    Read more | Download Document (367.66 kB)